Gene expression profiling during interference with PPAR gamma signaling in thoracic aorta

ABSTRACT: Pharmacological activation of the transcription factor PPAR gamma lowers blood pressure and improves glucose tolerance in humans. In contrast, naturally occurring mutations (e.g., P467L, V290M) in the ligand binding domain of PPAR gamma in humans leads to severe insulin resistance and early-onset hypertension. Experimental evidence, including whole genome expression profiling, suggests that these mutant versions of PPAR gamma act in a dominant negative manner. Because PPAR gamma is expressed in a variety of cell types and tissues, we generated a transgenic mouse model (SP467L) specifically targeting dominant negative PPAR gamma to the vascular smooth muscle cells in order to determine the action of PPAR gamma in the blood vessel independent of its systemic metabolic actions. In the data

ORGANISM(S): Mus musculus

SUBMITTER: Henry Keen 

PROVIDER: E-GEOD-37194 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress